Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN 7 versus AMINOSYN II 3 5 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN 7% vs AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 7% provides a mixture of essential and nonessential amino acids, serving as substrates for protein synthesis, thereby supporting nitrogen balance and tissue repair. It acts as a source of caloric nitrogen in parenteral nutrition.
Provides essential amino acids and dextrose for parenteral nutrition; amino acids serve as substrates for protein synthesis, while dextrose supplies caloric energy.
Intravenous: 500 mL to 2 L of 7% solution (35-140 g amino acids) per day by central or peripheral infusion, adjusted based on metabolic needs and nitrogen balance, usually infused at a rate not exceeding 0.1 g/kg/hour.
Individualized based on protein and calorie requirements; typical adult dose: 500-2000 mL/day intravenously, infused at a rate not exceeding 200 mL/hour.
None Documented
None Documented
Not applicable as a single entity; amino acids are utilized rapidly for protein synthesis and energy. Plasma amino acid levels decline with a terminal half-life of approximately 10-20 minutes post-infusion, reflecting rapid tissue uptake.
Variable, dependent on individual amino acids and metabolic state; clinical context reflects continuous infusion without distinct terminal phase.
Primarily renal elimination of infused amino acids as metabolic byproducts (urea, ammonia) and a small fraction of unchanged amino acids. Renal excretion accounts for >90% of elimination; negligible biliary/fecal.
Renal, primarily as urea and free amino acids; minimal biliary/fecal elimination.
Category C
Category C
Amino Acid Solution
Amino Acid Solution